Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).

NCT04441385 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

60

Enrollment

OTHER

Sponsor class

Stopped lack of viability

Conditions

COVID-19

Interventions

DRUG: Maraviroc 300 mg
OTHER: Standard care therapy

Sponsor

Hospital Universitario Infanta Leonor

Collaborators

[object Object]
[object Object]